Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures

Hussein, Haitham M.; Emiru, Tenbit; Georgiadis, Alexandros; Qureshi, Adnan I.

doi:10.3174/ajnr.a2963

Cited by 20 publications

(19 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By measuring the rate and extent of changes in light transmittance caused by platelets aggregating in whole blood samples, the VerifyNow system determines the level of platelet function in response to agonists (ADP/arachidonic acid). Blood samples with inhibited platelets produce a low level of light transmittance 10 14. The result of the platelet function assay is expressed as P2Y12 reaction units (PRUs) for clopidogrel and aspirin reaction units (ARUs) for aspirin.…”

Section: Methodsmentioning

confidence: 99%

Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms

Asai

Miyachi

Izumi

et al. 2015

J NeuroIntervent Surg

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms

Asai

Miyachi

Izumi

et al. 2015

J NeuroIntervent Surg

View full text Add to dashboard Cite

show abstract

“…Point-of-care testing was introduced because considerable differences can be observed within individuals in regard to platelet inhibition with the same doses of aspirin and clopidogrel. 26 Such assessment may allow the use of higher doses of clopidogrel and intravenous glycoprotein IIb/IIIa inhibitors among those with inadequate response (resistance) to standard doses of antiplatelet medication. The low rate of adverse events following intracranial angioplasty and stent placement in our trial raises the question of the superiority of such a procedure over intense medical treatment for high-grade symptomatic intracranial stenosis.…”

Section: Discussionmentioning

confidence: 99%

Multicenter Prospective Trial of Stent Placement in Patients with Symptomatic High-Grade Intracranial Stenosis

Gao

Wang

Zhao

et al. 2016

American Journal of Neuroradiology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:On the basis of the high 1-month stroke and/or death (14.7%) rates associated with stent placement in the Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trial, modifications in patient selection and procedural aspects for intracranial stent placement have been recommended. We performed a multicenter prospective single-arm trial to determine whether such modifications would result in lower rates of periprocedural stroke and/or death.

show abstract

“…sensitive to aspirin, with arachidonic acid asthe antagonist [73]. Given the fact that the system is based on the same concept as LTA, these two correlate well [81]. Its advantages are that it is standardised, easy to use, and requires no sample processing.…”

Section: Verifynow Testmentioning

confidence: 99%

“…Its advantages are that it is standardised, easy to use, and requires no sample processing. On the other hand, the system can be used only for monitoring anti-platelet therapy and is limited by platelet count and haematocrit as well as being is expensive [81].…”

Section: Verifynow Testmentioning

confidence: 99%

Anti-platelet Therapy Resistance – Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities

Mărginean

Bănescu

Scridon

et al. 2016

The Journal of Critical Care Medicine

View full text Add to dashboard Cite

It is well known that critically ill patients require special attention and additional consideration during their treatment and management. The multiple systems and organ dysfunctions, typical of the critical patient, often results in different patterns of enteral absorption in these patients. Anti-platelet drugs are the cornerstone in treating patients with coronary and cerebrovascular disease. Dual anti-platelet therapy with aspirin and clopidogrel is the treatment of choice in patients undergoing elective percutaneous coronary interventions and is still widely used in patients with acute coronary syndromes. However, despite the use of dual anti-platelet therapy, some patients continue to experience cardiovascular ischemic events. Recurrence of ischemic events is partly attributed to the fact that some patients have poor inhibition of platelet reactivity despite treatment. These patients are considered low-or nonresponders to therapy. The underlying mechanisms leading to resistance are not yet fully elucidated and are probably multifactorial, cellular, genetic and clinical factors being implicated. Several methods have been developed to asses platelet function and can be used to identify patients with persistent platelet reactivity, which have an increased risk of thrombosis. In this paper, the concept of anti-platelet therapy resistance, the underlying mechanisms and the methods used to identify patients with low responsiveness to anti-platelet therapy will be highlighted with a focus on aspirin and clopidogrel therapy and addressing especially critically ill patients.

show abstract

Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures

Cited by 20 publications

References 61 publications

Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms

Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms

Multicenter Prospective Trial of Stent Placement in Patients with Symptomatic High-Grade Intracranial Stenosis

Anti-platelet Therapy Resistance – Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities

Contact Info

Product

Resources

About